113 related articles for article (PubMed ID: 24881924)
1. [Effective control of skin reaction by air sandwich technique in a patient with IgE-κ myeloma treated with subcutaneous bortezomib injection].
Honda Y; Inoue J; Shingaki S; Miyazaki K; Abe Y; Sekine E; Iki S; Tsukada N; Suzuki K
Rinsho Ketsueki; 2014 May; 55(5):570-2. PubMed ID: 24881924
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O
Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772
[TBL] [Abstract][Full Text] [Related]
3. Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma.
Kamimura T; Miyamoto T; Takashima S; Yokota N; Chong Y; Ito Y; Akashi K
Int J Hematol; 2012 Oct; 96(4):525-7. PubMed ID: 22961216
[No Abstract] [Full Text] [Related]
4. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
5. An acceptable incidence of infusion site reactions after subcutaneous bortezomib administration in the upper arm in Japanese patients with multiple myeloma.
Ohgiya D; Tsuchiya T; Suyama T; Watanabe S; Numata H; Tsuboi K; Sasao T
Acta Haematol; 2015; 133(1):29-30. PubMed ID: 24993672
[No Abstract] [Full Text] [Related]
6. Subcutaneous bortezomib: a step towards optimised drug use.
Mateos MV
Lancet Oncol; 2011 May; 12(5):410-1. PubMed ID: 21507716
[No Abstract] [Full Text] [Related]
7. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
Richardson P
Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
[No Abstract] [Full Text] [Related]
8. Bortezomib and bilateral herpes zoster.
di Meo N; Bergamo S; Dondas A; Trevisan G
Acta Dermatovenerol Alp Pannonica Adriat; 2012; 21(1):21-2. PubMed ID: 22584902
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database.
Honton B; Despas F; Dumonteil N; Rouvellat C; Roussel M; Carrie D; Galinier M; Montastruc JL; Pathak A
Fundam Clin Pharmacol; 2014 Jun; 28(3):349-52. PubMed ID: 23781941
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Rekhtman G; Masliak Z; Robak P; Esseltine DL; Feng H; Deraedt W; van de Velde H; Arnulf B
Haematologica; 2015 May; 100(5):e207-10. PubMed ID: 25596270
[No Abstract] [Full Text] [Related]
11. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
Shah G; Kaul E; Fallo S; Cossor F; Smith H; Sprague K; Klein A; Miller K; Comenzo R
Clin Ther; 2013 Oct; 35(10):1614-20. PubMed ID: 24075726
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib-induced acute pancreatitis in a patient with multiple myeloma.
Wang HH; Tsui J; Wang XY; Liu SS; Li J
Leuk Lymphoma; 2014 Jun; 55(6):1404-5. PubMed ID: 23927397
[No Abstract] [Full Text] [Related]
13. Hyperlipidemia in a myeloma patient after bortezomib treatment.
Gozzetti A; Fabbri A; Defina M; Chitarrelli I; Bocchia M
Leuk Res; 2010 Sep; 34(9):e250. PubMed ID: 20363499
[No Abstract] [Full Text] [Related]
14. [Observational retrospective study to evaluate the effectiveness and safety of treatment schemes with bortezomib for multiple myeloma in our hospital].
Titos-Arcos JC; León-Villar J; de Arriba de la Fuente F; Moreno Belmonte MJ; Iranzo Fernández MD
Farm Hosp; 2012; 36(4):275-81. PubMed ID: 22115856
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous bortezomib: in multiple myeloma.
Hoy SM
Drugs; 2013 Jan; 73(1):45-54. PubMed ID: 23338539
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitor for treatment of multiple myeloma.
Ahmad K
Lancet Oncol; 2005 Aug; 6(8):546. PubMed ID: 16094754
[No Abstract] [Full Text] [Related]
17. The safety and efficacy of bortezomib in relapsed multiple myeloma.
Jagannath S
Clin Adv Hematol Oncol; 2006 May; 4(5):2-3; discussion 8; suppl 13. PubMed ID: 16830423
[No Abstract] [Full Text] [Related]
18. Bortezomib increases survival of patients with relapsed multiple myeloma.
Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
[No Abstract] [Full Text] [Related]
19. Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
Prescrire Int; 2006 Jun; 15(83):98-100. PubMed ID: 16764098
[TBL] [Abstract][Full Text] [Related]
20. Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma.
Zappasodi P; Dore R; Castagnola C; Astori C; Varettoni M; Mangiacavalli S; Lazzarino M; Corso A
J Clin Oncol; 2007 Aug; 25(22):3380-1. PubMed ID: 17664489
[No Abstract] [Full Text] [Related]
[Next] [New Search]